Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703856 · ClinicalTrials.gov registry record · Phase 4
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
A Phase 4 study of Alzheimer Disease, sponsored by University of California, San Diego.
- Active
- Registry status
- Phase 4
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT03703856: Active Phase 4 study of Alzheimer Disease, sponsored by University of California, San Diego.
NCT03703856 is a Phase 4 study of Alzheimer Disease that is active but no longer recruiting, run by University of California, San Diego. The registered enrollment target is 53 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03703856, a Phase 4 study of Alzheimer Disease, is active but no longer recruiting, sponsored by University of California, San Diego.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
Primary Outcome
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a tool used to assess the severity of cognitive impairment in individuals with Alzheimer's disease. It includes 11 tasks that evaluate memory, language, and praxis. The total score can range from 0 to 70 with higher scores indicating more severe impairment.
Conditions Studied
Interventions
- DRUG Memantine
Study Locations (1)
California
- Clinical Teaching Facility (CTF-B102) at UCSD Medical Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 4 |
What the registry record for NCT03703856 still lists
NCT03703856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Memantine is the first listed.
NCT03703856 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03703856 about?
NCT03703856 is a clinical study titled "Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease". The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
What is the current status of trial NCT03703856?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 53 participants. The study started on 2019-01-31. Estimated completion is 2025-12-30.
What conditions does trial NCT03703856 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03703856?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT03703856?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03703856 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03703856's enrollment target sits among peer trials
53 206th of 306 higher than 101 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
The Depression in Alzheimer's Disease Study (DIADS)
COMPLETED · Phase 4
-
Antipsychotic Discontinuation in Alzheimer's Disease
COMPLETED · Phase 4
-
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI